
A
Abscopal
Treatment
Tumor area (mm2)
Days post implant
CT26
Percent survival
NKTR-214/RT
rhIL-2/RT
Control
B
CD4+, FOXP3+
CD4+, FOXP3-
CD8+
NKp46+
Treg, CD62L+
Treg, GranzA+
Treg, Ki-67+
Treg, CD122+
Teff, CD62L+
Teff, GranzA+
Teff, Ki-67+
Teff, CD122+
CD8+, CD25+
CD8+, ICOS+
CD8+, PD-1+
CD8+, TIM3+
CD8+, CD62L+
CD8+, GranzA+
CD8+, Ki-67+
CD8+, CD122+
% of CD4+ Population
% of CD45+ Population
% of Treg+ Population
% of Teff+ Population
% of CD8+ Population